PVantage™ Safety Data Automation
Pharmacovigilance Adverse Event Management Platform
PVantage is a modular offering, able to scale with your program as case volume increases.
PVantage™ is an innovative platform, that allows drug safety teams to streamline and automate case processing activities to ensure accuracy, efficiency, and compliance. This tool works with clinical trial and post market safety data and provides the ability to integrate, analyze, and visualize patient, program, and drug class information for greater control and oversight of your safety data.
PVantage is a proprietary cloud-based solution that allows Sponsors to elect the degree of automation of all workflows for case intake, case processing, safety data analysis and generation of standard reports. A dedicated, virtual managed environment provides Sponsors with a consistently updated platform and assures compliance with ever-changing global pharmacovigilance regulations.
Click to learn more about Comprehensive Safety Solutions to accompany this technology.
Allows for the automation and streamlining of case intake, including autopopulation of case data from a variety of sources
This module enables efficient and seamless data exchange between the Clinical electronic data capture (EDC) system and the Safety database, resulting in time reduction for case processing and data reconciliation while providing increases in quality.
PVantage dashboards allow for the visualization of complex safety data, making it easier to understand and interpret the data using a wide range of visualization options. The customizable data visualization layer allows for near real-time data inquiry and more informed decisions. In addition, sponsors can customize reporting content and cadence, including status reports, cumulative safety listings, KPIs, and other compliance reports.
With PVantage, Sponsors gain an accelerated technological advantage with greater visualization and efficient reporting of safety data.
Suggested For You
regulatory intelligence
January 17th, 2025
The FDA’s AI Guidance and its Seven Steps into the Future of Drug Development
regulatory intelligence
January 17th, 2025
New FDA Protocol Deviation Guidance: Planning for the Things That Don’t Go According to Plan
perspectives
January 9th, 2025
How to Create Efficiencies When Creating Simultaneous NDA and MAA Submissions for the FDA and EMA
perspectives
January 2nd, 2025
Informed Consent in Clinical Research: Understanding its Significance and Sponsor Obligations
perspectives
December 17th, 2024
Oncology Drug Development: Webinar Learnings on the Use of Expedited Pathways and Oncology Center of Excellence Programs
perspectives
December 11th, 2024
Why Emerging Biotech Companies are Increasingly Turning to Specialized Data CROs
regulatory intelligence
December 4th, 2024
FDA Issues Detailed Guidance on Development of Gene Therapy Products
news
December 4th, 2024
AI in Pharma and Innovative Leadership Were on Display at the Biennial MMS Scientific Symposium
perspectives
November 26th, 2024
Finding GRASEland: Navigating the New Regulatory Path for Grandfathered OTC Drugs
perspectives
November 21st, 2024
Essential Nonclinical Strategies for Cell and Gene Therapy (CGT) Success
news
November 19th, 2024
MMS Recognized as a Top Workplace by Detroit Free Press and USA Today Network for the Fourth Consecutive Year
perspectives
November 12th, 2024
REMS Logic Modeling: Applying FDA Guidance from November 2024 CDER Webinar